FDA reviewers were not able to cast votes on the initial priority voucher medication.
Key Takeaways The FDA is streamlining its drug review process for companies that earn a Commissioner’s National Priority Voucher. Recently, agency leaders made decisions on drug approvals instead of career officials, raising concerns about political influence. The approval process is now capped at a one-to-two-month timeline, with a focus on efficiency. Understanding Recent Changes at …









